TD Asset Management Inc Purchases 21,005 Shares of Hologic, Inc. $HOLX

Key Points

• TD Asset Management Inc has increased its stake in Hologic, Inc. by 1.4% in Q2 2023, now owning approximately 1.53 million shares valued at $99.7 million.
• Hologic reported an EPS of $1.08 for the last quarter, surpassing analyst expectations of $1.05, with a revenue of $1.02 billion.
• Analysts have varied ratings for Hologic, with Citigroup upgrading the stock from "neutral" to "buy" and setting a target price of $80, reflecting a positive outlook from multiple firms.

TD Asset Management Inc boosted its position in Hologic, Inc. (NASDAQ:HOLX - Free Report) by 1.4% in the second quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 1,530,317 shares of the medical equipment provider's stock after purchasing an additional 21,005 shares during the quarter. TD Asset Management Inc owned approximately 0.69% of Hologic worth $99,715,000 at the end of the most recent reporting period.

A number of other large investors have also added to or reduced their stakes in the company. Greenleaf Trust raised its holdings in Hologic by 5.1% in the second quarter. Greenleaf Trust now owns 3,579 shares of the medical equipment provider's stock worth $233,000 after purchasing an additional 173 shares in the last quarter. Beverly Hills Private Wealth LLC raised its holdings in Hologic by 3.6% in the first quarter. Beverly Hills Private Wealth LLC now owns 5,173 shares of the medical equipment provider's stock worth $320,000 after purchasing an additional 180 shares in the last quarter. Allworth Financial LP raised its holdings in Hologic by 46.0% in the first quarter. Allworth Financial LP now owns 686 shares of the medical equipment provider's stock worth $40,000 after purchasing an additional 216 shares in the last quarter. First American Bank raised its holdings in Hologic by 0.9% in the second quarter. First American Bank now owns 28,705 shares of the medical equipment provider's stock worth $1,870,000 after purchasing an additional 245 shares in the last quarter. Finally, SPC Financial Inc. raised its holdings in Hologic by 2.2% in the second quarter. SPC Financial Inc. now owns 12,859 shares of the medical equipment provider's stock worth $838,000 after purchasing an additional 278 shares in the last quarter. 94.73% of the stock is currently owned by institutional investors.

Hologic Price Performance

Shares of NASDAQ HOLX opened at $65.92 on Wednesday. The business's 50 day moving average price is $67.06 and its 200 day moving average price is $63.38. The firm has a market cap of $14.66 billion, a P/E ratio of 27.35, a P/E/G ratio of 2.25 and a beta of 0.63. Hologic, Inc. has a 52 week low of $51.90 and a 52 week high of $84.39. The company has a quick ratio of 2.81, a current ratio of 3.55 and a debt-to-equity ratio of 0.52.

Hologic (NASDAQ:HOLX - Get Free Report) last issued its earnings results on Wednesday, July 30th. The medical equipment provider reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $1.05 by $0.03. The firm had revenue of $1.02 billion for the quarter, compared to analyst estimates of $1.01 billion. Hologic had a return on equity of 19.69% and a net margin of 13.79%.Hologic's revenue for the quarter was up 1.2% on a year-over-year basis. During the same quarter in the prior year, the firm earned $1.06 earnings per share. Hologic has set its Q4 2025 guidance at 1.090-1.120 EPS. FY 2025 guidance at 4.230-4.260 EPS. On average, sell-side analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Insider Buying and Selling

In related news, CEO Stephen P. Macmillan sold 138,358 shares of the company's stock in a transaction that occurred on Monday, September 22nd. The stock was sold at an average price of $66.97, for a total value of $9,265,835.26. Following the sale, the chief executive officer owned 1,234,624 shares in the company, valued at $82,682,769.28. This represents a 10.08% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. 1.88% of the stock is currently owned by corporate insiders.

Wall Street Analyst Weigh In

A number of equities analysts have commented on HOLX shares. Citigroup upgraded shares of Hologic from a "neutral" rating to a "buy" rating and boosted their target price for the stock from $60.00 to $80.00 in a report on Wednesday, July 9th. Argus boosted their price target on Hologic from $80.00 to $90.00 and gave the stock a "buy" rating in a research note on Friday, September 19th. UBS Group boosted their price target on Hologic from $65.00 to $70.00 and gave the stock a "neutral" rating in a research note on Thursday, July 31st. Morgan Stanley boosted their price target on Hologic from $65.00 to $69.00 and gave the stock an "equal weight" rating in a research note on Thursday, July 31st. Finally, Evercore ISI set a $78.00 price target on Hologic and gave the stock an "outperform" rating in a research note on Tuesday, October 7th. One research analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating and eight have given a Hold rating to the company. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and a consensus price target of $80.15.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.